Dimarakis Ioannis, Callan Paul, Khorsandi Maziar, Pal Jay D, Bravo Claudio A, Mahr Claudius, Keenan Jeffrey E
Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States.
Department of Cardiothoracic Transplantation, Manchester University Hospital NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom.
Front Cardiovasc Med. 2022 Nov 3;9:1029825. doi: 10.3389/fcvm.2022.1029825. eCollection 2022.
Over the last two decades, implantable continuous flow left ventricular assist devices (LVAD) have proven to be invaluable tools for the management of selected advanced heart failure patients, improving patient longevity and quality of life. The presence of concomitant valvular pathology, including that involving the tricuspid, mitral, and aortic valve, has important implications relating to the decision to move forward with LVAD implantation. Furthermore, the presence of concomitant valvular pathology often influences the surgical strategy for LVAD implantation. Concomitant valve repair or replacement is not uncommonly required in such circumstances, which increases surgical complexity and has demonstrated prognostic implications both short and longer term following LVAD implantation. Beyond the index operation, it is also well established that certain valvular pathologies may develop or worsen over time following LVAD support. The presence of pre-existing valvular pathology or that which develops following LVAD implant is of particular importance to the destination therapy LVAD patient population. As these patients are not expected to have the opportunity for heart transplantation in the future, optimization of LVAD support including ameliorating valvular disease is critical for the maximization of patient longevity and quality of life. As collective experience has grown over time, the ability of clinicians to effectively address concomitant valvular pathology in LVAD patients has improved in the pre-implant, implant, and post-implant phase, through both medical management and procedural optimization. Nevertheless, there remains uncertainty over many facets of concomitant valvular pathology in advanced heart failure patients, and the understanding of how to best approach these conditions in the LVAD patient population continues to evolve. Herein, we present a comprehensive review of the current state of the field relating to the pathophysiology and management of valvular disease in destination LVAD patients.
在过去二十年中,植入式连续血流左心室辅助装置(LVAD)已被证明是治疗特定晚期心力衰竭患者的宝贵工具,可提高患者的寿命和生活质量。合并存在的瓣膜病变,包括涉及三尖瓣、二尖瓣和主动脉瓣的病变,对于决定是否进行LVAD植入具有重要意义。此外,合并存在的瓣膜病变通常会影响LVAD植入的手术策略。在这种情况下,常常需要进行瓣膜修复或置换,这增加了手术的复杂性,并已证明对LVAD植入后的短期和长期预后都有影响。除了初次手术外,也有充分证据表明,在LVAD支持后,某些瓣膜病变可能会随着时间的推移而发展或恶化。预先存在的瓣膜病变或LVAD植入后出现的病变对于接受目标治疗的LVAD患者群体尤为重要。由于预计这些患者未来没有机会进行心脏移植,优化LVAD支持,包括改善瓣膜疾病,对于最大限度地延长患者寿命和提高生活质量至关重要。随着时间的推移,临床医生在LVAD植入前、植入中和植入后阶段,通过药物治疗和手术优化,有效处理LVAD患者合并瓣膜病变的能力有所提高。然而,晚期心力衰竭患者合并瓣膜病变的许多方面仍存在不确定性,对于如何在LVAD患者群体中最佳处理这些情况的认识也在不断发展。在此,我们对目标治疗LVAD患者瓣膜疾病的病理生理学和管理领域的现状进行全面综述。